anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is a prospective, randomized, controlled study, follow the principle of PICOST design, specific as follows: Participants (the list) : preliminary clinical diagnosis of coronary atherosclerotic heart disease, heart failure. Intervention (Intervention) : conventional drug therapy + new cardiac rehabilitation therapy, a new cardiac rehabilitation treatment reference guide requirements, according to the actual circumstance of patients treated with 1-3 months Intervention. Comparator(control): conventional drug therapy + traditional cardiac rehabilitation therapy. The traditional cardiac rehabilitation therapy referred to domestic and international guidelines and consensus, and used 1 week-3 months of treatment intervention according to the actual situation of patients. Outcome (the end) : the primary end point: D_SPECT examination, were followed up for 6 months to evaluate myocardial perfusion imaging is reduce ischemic area. The secondary end point: 1) the blood biochemical examination and myocardial necrosis markers, etc.; 2) the cardiopulmonary exercise testing: maximum kilograms oxygen uptake and anaerobic threshold when the maximum kilograms oxygen uptake; 3) the major adverse cardiovascular events: cardioascular death, non-fatal myocardial infarction, unplanned coronary artery reconstruction, stroke, heart failure and angina associated hospitalized again; 4) patients family rehabilitation treatment adherence
In addition to the routine care provided according to the Turkish Ministry of Health's Prenatal Care Management Guidelines, the intervention group will receive a mobile application intervention. The intervention (mobile application) will begin at the 12th week of pregnancy. Participants in the intervention group will start using the mobile application at the 12th week of pregnancy and continue to use it throughout their pregnancy. The content of the mobile application includes information on healthy nutrition and exercise during pregnancy, as well as monitoring and notifications. Pregnant women will be guided, encouraged, and monitored for healthy nutrition and exercise through the mobile application.
In a 26 week, double-blind, placebo-controlled trial, a total of 527 patients already on metformin (mean baseline A1C = 8%) were randomized to receive alogliptin 12.5 mg, alogliptin 25 mg, or placebo once daily. Patients were maintained on a stable dose of metformin HCl (median daily dose = 1700 mg) during the treatment period. Alogliptin 25 mg in combination with metformin resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, when compared to placebo (Table 7). A total of 8% of patients receiving alogliptin 25 mg and 24% of patients receiving placebo required glycemic rescue. Improvements in A1C were not affected by gender, age, race, baseline BMI or baseline metformin dose.

The mean decrease in body weight was similar between alogliptin 25 mg and placebo when given in combination with metformin. Lipid effects were also neutral.
PROBLEM TO BE SOLVED: To obtain an antiseptic for cosmetics capable of manifesting remarkably high antiseptic and bactericidal effects by using fine powder of a specific mineral and its action to enhance surface activities of water, alcohol, etc. SOLUTION: In this antiseptic for cosmetics, fine powder of a material called tourmaline is used. Tourmaline is a silicate mineral containing boron and belongs to a trigonal or a hexagonal hemimorphic hemihedral form which is asymmetric in above and below. Its chemical formula is complicated and the typical one is expressed by the formula (X is Mg, Fe, Li, etc.). Tourmaline is more excellent in chemical resistances against acids, alkalies, etc., than silica. Thus, when mixed in cosmetics, no chemical reaction occurs with the acids and the alkalies included in the cosmetic components. When tourmaline is brought into contact with water, it is electrolyzed by its action as permanent electrodes and has a function to emulsify and disperse an oil component in water as hydroxyl ions formed by the electrolysis which exhibit a surface activity.  The fine particles have preferably <=10μm particle size.
Chronic hypoxia (CH) is commonly associated with various cardiovascular diseases, with cardiac hypertrophy being the most frequently observed alteration. Metabolic remodeling is another consequence seen in the hypoxic heart. However, the mechanistic linkage between metabolic remodeling and cardiac hypertrophy in the hypoxic heart remains unclear. In this study, wild-type C57BL/6J mice were subjected to CH for 4 wk. Echocardiography and morphological analysis were used to assess the cardiac effects. We found that 4 wk of CH led to significant cardiac hypertrophy in the mice, whereas cardiac function remained unchanged compared with normoxic mice. In addition, CH induced an elevation in cardiac alpha-ketoglutarate (α-KG) content. Promoting α-KG degradation in the CH hearts prevented CH-induced cardiac hypertrophy but led to noticeable cardiac dysfunction. Mechanistically, α-KG promoted the transcription of hypertrophy-related genes by regulating histone methylation. Silencing lysine-specific demethylase 5 (KDM5), a histone demethylation enzyme, blunted α-KG-induced transcription of hypertrophy-related genes. These data suggest that α-KG is required for CH-induced cardiac remodeling, thus establishing a connection between metabolic changes and cardiac remodeling in hypoxic hearts.NEW & NOTEWORTHY We reported that alpha-ketoglutarate (α-KG) is indispensable for chronic hypoxia (CH)-induced cardiac remodeling, which builds the bridge between metabolic intermediates and cardiac remodeling.
Disclosed are techniques, devices and systems that provide adjustments to parameter settings of an insulin delivery algorithm based on inputs from a number of generic sensor devices. A majority of the generic sensor devices provide sensor readings that are unused as inputs to a drug deliver algorithm. The generic sensor devices may be operable to detect characteristics, such as changes in a state of a user. A processor may evaluate a sensor reading provided by a particular sensor with respect to a sensor baseline reading for the particular sensor. Using the result of the evaluation, the processor may calculate an adjustment to a parameter setting or settings of a medication delivery algorithm. A dosage of medication may be modified based on the adjustment of the parameter setting or settings.
PURPOSE:To provide a liq. detergent compsn. exhibiting excellent temp. stability and foaming properties and giving excellent feeling in its use, by blending a particular N-acyl amino acid salt and behenyl alcohol in predetermined proportions. CONSTITUTION:4-30wt.% at least one N-acyl amino acid salt (A) of the formula (wherein R1 is a 7-21C alkyl or alkenyl; each of M1 and M2 is H, an alkali metal or an alkanolamine; and n is 1-2) (e.g., monotriethanolamine salt of N- lauroylglutamic acid) and 0.2-5wt.% behenyl alcohol (B) are incorporated, thereby producing a liq. detergent compsn. The behenyl alcohol is a 22C straight-chain, satd. monohydric alcohol, and can be produced by various methods including one comprising subjecting a fatty acid, e.g., obtd. from rapeseed oil to hydrogen reduction under a high pressure and performing distillation for purification. The obtd. detergent compsn. can advantageously be used as a shampoo, etc.
A patch delivers a volatile substance to an environment. The patch provides the volatile substance within a solid layer positioned between a breathable layer and a barrier layer. A release liner is removably adhered to the barrier layer. The solid layer may be formed by mixing the volatile substance with a liquid agent that forms a solid below 40°C. The liquid mixture is applied to the breathable layer and allowed to solidify. The other layers are added thereto.
The BIPASS-AKI study is intended to evaluate participants who are at an increased risk of developing cardiac surgery-associated acute kidney injury (CSA-AKI), and, subsequently, overall poor outcomes. Patients to be considered for participation include those undergoing elective or urgent in-house on-pump cardiac surgery (to include coronary artery bypass graft, valvular surgery, or combination) and have pre-existing renal insufficiency as defined by a pre-operative eGFR between 15-60 mL/min. Participants meeting inclusion and exclusion criteria will be enrolled into a treatment arm (single-arm study) following the completion of informed consent. Participants will receive implantation of the JuxtaFlow Catheters following completion of the their cardiac surgery while remaining under anesthesia. Treatment with the JuxtaFlow System will be initiated upon the participant's arrival into the intensive care unit and continue for up to 24 hours post-operatively. Preoperative, intra-operative, and post-operative data will be collected on participants to include 15- and 30-day follow-up periods.
Subject included in the active group will receive Bacmune. The dose consists on 2 spray puff every 12 hours for 45 days.
PURPOSE:To uniformize the properties of the carrier without inducing a nonspecific reaction by treating gelatin, metaphosphate and anion surfactant with an aldehyde compd. CONSTITUTION:The uniform artificial carrier is obtd. by treating the gelatin, metaphosphate and anion surfactant with the aldehyde compd.. The gelatin may be commercially marketed gelatin and the acidic gelatin which can control the surface potential of the artificial carrier is more particularly preferable. The metaphosphate is the compd. expressed by formula: (MPO3)n (M is an Na atom or K atom; n is 3 to 6). More concretely, there are various kinds, such as Na trimetaphosphate, etc., and the use of Na hexametaphosphate is more preferable. The anion surfactant is a higher fatty acid salt, alkyl sulfate, etc., and more concretely, Na dodecyl sulfate is more preferable. The aldehyde compd. is formalin, glyoxal, etc., and glutaraldehyde is adequately used.
Chronic obstructive pulmonary disease (COPD) in a patient can be treated by administering to said patient an effective dose of an extract of Petasites sp. Preferred dosages are in the range of from about 1 to about 50 mg/kg per day or above and have been shown to be effective in treating COPD in horses. Thus, medicaments for treating COPD can be provided by using an extract ofPetasites sp. for preparation of such medicaments. The novel treatment of COPD is of particular advantage in the case of horses but it is expected that human patients can be treated successfully as well. Such treatment is of particular importance if use of corticosteroids for treating broncho-constrictive or broncho-obstructive diseases is impossible or undesirable.
A craving control device comprising a housing, a craving input actuator supported by the housing, a wireless communicator supported by the housing, and a controller is provided. The craving input actuator can be configured to obtain information from a user pertaining to a timing, frequency, or intensity of a craving. The controller can be operatively connected to the craving input actuator and the wireless communicator to communicate craving information received by the craving input actuator via the wireless communicator to a device external to the housing. The device external to the housing can be a personal communication device. The housing can be sized and configured to be enclosed in the user's hand and or to be placed in a pocket of the user's clothing. Methods for using the craving control devices are also provided.
Provided are antibody drug conjugates (ADC's) that comprise an anti-158P1D7 antibody or an antigen binding fragment and monomethyl auristatin E (MMAE). 158P1D7 exhibits tissue specific expression in normal adult tissues, but is aberrantly expressed in cancers. Consequently, the ADC's of the invention are provided for treating cancer selected from glioblastoma, lung cancer, breast cancer and bladder cancer. The invention further provides therapeutic compositions comprising a therapeutically effective amount of the ADC of the invention and which are provided for treating glioblastoma, lung cancer, bladder cancer or breast cancer. Also provided are methods of producing an antibody drug conjugate of the invention and a polynucleotide, a vector and a host cell that are used for expressing an antibody in accordance with the methods of producing the ADC. Finally, provided are methods of treating bladder cancer in a subject, comprising either administering to said subject only an ADC of the invention or administering to the subject an ADC of the invention and further therapeutic treating by radiation or administering a chemotherapeutic agent.
Angiogenesis is well known to play a critical role in breast cancer. We previously reported that TNFAIP2 activates Rac1 to promote triple-negative breast cancer (TNBC) cell proliferation, migration, and chemoresistance. However, the potential contribution of TNFAIP2 to tumor angiogenesis remains unknown. In this study, we demonstrated that TNFAIP2 promotes TNBC angiogenesis by activating the Rac1-ERK-AP1-HIF1α signaling axis. Under hypoxia, TNFAIP2 activates Rac1 and ERK sequentially. Following that, ERK activates the AP-1 (c-Jun/Fra1) transcription factor. By employing chromatin immunoprecipitation and luciferase reporter assays, we showed that AP-1 directly interacts with the HIF1α gene promoter, thereby enhancing its transcription. The combined application of ERK inhibitors, U0126 or trametinib, with the VEGFR inhibitor Apatinib, additively suppresses angiogenesis and tumor growth of HCC1806 in nude mice. These findings provide new therapeutic strategies for TNBC.
FIELD: cosmetics. SUBSTANCE: invention relates to cosmetic compositions containing in cosmetically acceptable medium copolymer of methacrylic acid with C 1 -C 4 -alkylacrylate, cationic or amphoteric polymer and silicone comprising functional groups. These compositions are used, in part, for washing and/or conditioning keratin materials, such as hair and skin. Invention provides conferring to keratin materials good cosmetic properties, in part, lightness, softness, smoothness to the touch and flexibility and obedient to dried hair also. EFFECT: improved and valuable properties of composition. 41 cl, 2 tbl
PCT No. PCT/JP97/03484 Sec. 371 Date Jun. 15, 1999 Sec. 102(e) Date Jun. 15, 1999 PCT Filed Sep. 30, 1997 PCT Pub. No. WO98/14753 PCT Pub. Date Apr. 9, 1998The present invention provides an iminochlorin aspartic acid derivative represented by the following formula (I): Wherein Asp represents an aspartic acid residue, or a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a photosensitizer for photophysico-chemical diagnosis and therapy of cancer, because it has a high accumulability to cancerous cells, reactivity to external energy and a cancerous cell destroying effect which is effective even against cancers developing in deep site, while it is rapidly excreted from normal cells and therefore causes no damage thereto.
PURPOSE OF REVIEW: Percutaneous nephrolithotripsy (PCNL) is the first-line management option for large kidney stones (>2 cm). It remains, however, a demanding procedure with considerable morbidity. The present narrative review summarizes recent knowledge from original research studies investigating navigation systems/three-dimensional (3D) imaging in PCNL, particularly on publications during the past 12-18 months.
RECENT FINDINGS: Navigation systems and 3D imaging are primarily used for preoperative planning, with few intra-operative applications. Patient management and residents' training could benefit from their use.
SUMMARY: Navigation systems and 3D imaging technology have emerged as a potential game-changer in PCNL. Even though available evidence is currently scarce/inconclusive, the safety/efficacy of navigation systems and 3D dimensional imaging use in PCNL appears promising. This advanced technology offers precise anatomical mapping, improved visualization, and surgical accuracy. Enabling a comprehensive preoperative evaluation and improving guidance, navigation systems, and 3D imaging technology may improve the safety and efficacy of PCNL. With continuous technological evolution, it is expected that improvements/innovations will offer further aid in such demanding procedures. Familiarization and cost reduction are necessary for widespread application, while larger-scale prospective studies and well designed randomized controlled trials are still needed.
Cardiac implantable electronic device-related infective endocarditis (CIED-IE) encompasses a range of clinical syndromes, including valvular, device lead, and bloodstream infections. However, accurately diagnosing CIED-IE remains challenging owing in part to diverse clinical presentations, lack of standardized definition, and variations in guideline recommendations. Furthermore, current diagnostic modalities, such as transesophageal echocardiography and [18F]-fluorodeoxyglucose positron emission tomography-computed tomography have limited sensitivity and specificity, further contributing to diagnostic uncertainty. This can potentially result in complications and unnecessary costs associated with inappropriate device extraction. Six hypothetical clinical cases that exemplify the diverse manifestations of CIED-IE are addressed herein. Through these cases, we highlight the importance of optimizing diagnostic accuracy and stewardship, understanding different pathogen-specific risks for bloodstream infections, guiding appropriate device extraction, and preventing CIED-IE, all while addressing key knowledge gaps. This review both informs clinicians and underscores crucial areas for future investigation, thereby shedding light on this complex and challenging syndrome.
Our study was designed as a randomized, single-blind experimental clinical trial. It was planned to include 40 individuals diagnosed with bruxism in our research. Outcome measurements and assessments will be performed immediately after the participants are recruited and at the end of the 8-week program. Pain intensity, oral health quality of life, stress level and sleep quality will be assessed by self-report through questionnaires. Pressure pain threshold and muscle activation for the masseter muscle and heart rate variables measurements will be performed by physiotherapists. After completing the initial evaluations, the participants will be randomly divided into two groups. An eight-week exercise program will be applied to the control group. In the TAVNS group, in addition to the eight-week exercise program, TAVNS will be used twice weekly for 16 sessions with the VAGUSTIM device.
The invention belongs to the technical field of enhancing the effect of medicaments, and particularly relates to a method for enhancing the effect of arsenic trioxide on intracranial tumors and application thereof. The feasibility of LIUS as a sensitizer for increasing the anti-glioma effect of ATO is verified from in vivo and in vitro levels. The results suggest that after LIUS combined with ATO, the drug effect is enhanced, the drug concentration in brain tissue is increased, and ATO can play a certain role in resisting glioma under the condition of human body safe dosage. Meanwhile, the ATO + LIUS proves that the purpose of inhibiting proliferation is achieved by increasing apoptosis of U87MG and cell death caused by autophagy of U251. LIUS in combination with ATO is a promising new approach to treatment of glioma, improving prognosis. Has great clinical significance.
The invention relates to nanoparticles for the administration of biologically active molecules comprising a biodegradable polymer, preferably the copolymer of methyl vinyl ether and maleic anhydride (MVE/MA), and thiamine. Such nanoparticles are simply produced having excellent characteristics of bioadhesion, size and zeta potential, rendering them suitable for the administration of active molecules. The procedure of obtainment of such nanoparticles is realised by simple incubation for a short period of time, the nanoparticles being preformed in an aqueous medium. The biologically active molecule may be incorporated during the process of formation of the nanoparticles by desolvation or through modification with thiamine. By oral route said nanoparticles develop bioadhesive interactions with the gastrointestinal mucous membrane, including the lymphoid tissue associated with mucous membranes (Peyer's patches), and are therefore useful for increasing the oral bioavailability of various drugs or inducing immune responses in mucous membranes. Thus when such nanoparticles contain an antigen within the matrix thereof the resultant mixture is capable of inducing strong immune responses to the encapsulated antigen. Such stimulating effect on immune response is useful in vaccination and immunotherapy.
BACKGROUND: This cross-sectional study investigates infection prevention and control (IPC) competencies among healthcare professionals in northwest China, examining the influence of demographic factors, job titles, education, work experience, and hospital levels.
METHODS: Data from 874 respondents across 47 hospitals were collected through surveys assessing 16 major IPC domains. Statistical analyses, including Mann-Whitney tests, were employed to compare competencies across variables.
RESULTS: Significant differences were identified based on gender, job titles, education, work experience, and hospital levels. Females demonstrated higher IPC competencies, while senior positions exhibited superior performance. Higher educational attainment and prolonged work experience positively correlated with enhanced competencies. Variances across hospital levels underscored context-specific competencies.
CONCLUSION: Demographic factors and professional variables significantly shape IPC competencies. Tailored training, considering gender differences and job roles, is crucial. Higher education and prolonged work experience positively impact proficiency. Context-specific interventions are essential for diverse hospital settings, informing strategies to enhance IPC skills and mitigate healthcare-associated infections effectively.
Exercises including upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group, 5 sessions per week for 6 weeks. Since the functional recovery of the upper extremity after stroke will be slow, the exercise program is planned to be 5 days a week due to the necessity of applying an intense exercise program in the early period. All patients will be asked to perform exercises under the supervision of a physiotherapist as a home program on other days of the week.